IMMUNIC, INC. — Director's Dealing 2019

Jan 14, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VITAL THERAPIES INC (VTL)
CIK: 0001280776
Period of Report: 2019-01-11

Reporting Person: Swanson Michael V. (Chief Financial Officer, EVP)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-01-11	Stock Option (right to buy)	$8.0	D	90000	Disposed	2023-09-08	Common Stock (90000.0)	Direct
2019-01-11	Stock Option (right to buy)	$8.28	D	75000	Disposed	2026-05-12	Common Stock (75000.0)	Direct
2019-01-11	Stock Option (right to buy)	$3.2	D	75000	Disposed	2027-06-09	Common Stock (75000.0)	Direct
2019-01-11	Stock Option (right to buy)	$5.0	D	75000	Disposed	2028-06-08	Common Stock (75000.0)	Direct
2019-01-11	Restricted Stock Units	$	A	817826	Acquired		Common Stock (817826.0)	Direct

Footnotes

F1: The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation.

F2: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")), one forty-eighth (1/48th) of the shares subject to the option vested and became exercisable one month after the vesting commencement date of April 16, 2016, and an additional one forty-eighth (1/48th) of the shares vest and become exercisable at the end of each monthly period thereafter. One hundred percent (100%) of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan).

F3: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")), one forty-eighth (1/48th) of the shares subject to the option vested and became exercisable one month after the vesting commencement date of June 10, 2017, and an additional one forty-eighth (1/48th) of the shares vest and become exercisable at the end of each monthly period thereafter. One hundred percent (100%) of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan).

F4: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")), one forty-eighth (1/48th) of the shares subject to the option vested and became exercisable one month after the vesting commencement date of June 9, 2018, and an additional one forty-eighth (1/48th) of the shares vest and become exercisable at the end of each monthly period thereafter. One hundred percent (100%) of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan).

F5: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Vital Therapies, Inc. Common Stock.

F6: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan), twenty five percent (25%) of the RSUs vest annually after the vesting commencement date of January 11, 2019. One hundred percent (100%) of the unvested portion of the RSUs, if any, shall vest in the event of a Termination without Cause or Resignation for Good Reason (each as defined in the reporting person's Change of Control and Severance Agreement).